The French National Agency for the ANSM approved Transgene’s CTA for the company to proceed into P-I clinical trial (Delivir) to evaluate TG6050 for which the 1st patient is expected to be enrolled by H1’23
The P-I clinical trial (Delivir) will evaluate TG6050 (IV, single & repeated escalating doses) in patients (n=36) with metastatic/advanced NSCLC who have failed standard therapeutic options incl. ICIs across multiple locations
TG6050 is an oncolytic virus developed using the company’s Invir.IO platform & has been engineered to encode human IL-12 stimulating a powerful antitumor immune response and a full-length anti-CTLA4 Ab
Ref: BusinessWire | Image: Transgene
Related News:- AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies
